GlycoMimetics, Inc. (GLYC) Initiates First Clinical Trial Of GMI-1271 As Potential Treatment For Blood-Related Cancers
6/19/2014 9:19:26 AM
GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that the first healthy volunteer has been dosed in a Phase 1 clinical study designed to evaluate the safety, tolerability and pharmacokinetics of GMI-1271, a novel and proprietary E-selectin antagonist in the company’s pipeline. GlycoMimetics is initially exploring the clinical use of the drug candidate to treat acute myeloid leukemia (AML) following preclinical studies of GMI-1271 for blood cancers and other cancers that are associated with elevated risk of metastasis and thrombosis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by